Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Retained Earnings (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Retained Earnings data on record, last reported at $265000.0 in Q3 2025.

  • For Q3 2025, Retained Earnings rose 100.26% year-over-year to $265000.0; the TTM value through Sep 2025 reached $265000.0, up 100.26%, while the annual FY2024 figure was -$117.4 million, 108805.56% down from the prior year.
  • Retained Earnings reached $265000.0 in Q3 2025 per CTNM's latest filing, up from $147000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $265000.0 in Q3 2025 and bottomed at -$117.4 million in Q4 2024.
  • Average Retained Earnings over 3 years is -$27.5 million, with a median of $25000.0 recorded in 2023.
  • Peak YoY movement for Retained Earnings: plummeted 108805.56% in 2024, then soared 393.1% in 2025.
  • A 3-year view of Retained Earnings shows it stood at $108000.0 in 2023, then tumbled by 108805.56% to -$117.4 million in 2024, then skyrocketed by 100.23% to $265000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $265000.0 in Q3 2025, $147000.0 in Q2 2025, and $170000.0 in Q1 2025.